Raymond James Financial
INO icon

Raymond James Financial’s Inovio Pharmaceuticals INO Stock Holding History

Raymond James Financial’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8K Sell
16,543
-145
-0.9% -$239 ﹤0.01% 5180
2025
Q4 		$29K Buy
16,688
+8
+0% +$18 ﹤0.01% 5059
2025
Q3 		$39K Buy
16,680
+16,309
+4,396% +$31.2K ﹤0.01% 4850
2025
Q2 		$755 Buy
+371
New +$711 ﹤0.01% 6613

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's INO Position: Q1 2026 in Review

Raymond James Financial reduced its Inovio Pharmaceuticals (INO) stake by 0.87% in Q1 2026, selling an estimated $239 and leaving 16,543 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5180.

Raymond James Financial first reported a position in INO in Q2 2025 and has held it in 4 quarters since. The position peaked at $39K in Q3 2025. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Raymond James Financial held 16,543 shares of Inovio Pharmaceuticals worth $28.8K as of Q1 2026.
  • Raymond James Financial sold 145 Inovio Pharmaceuticals shares in Q1 2026, an estimated $239.
  • Inovio Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5180 holding.
  • Raymond James Financial first reported a position in Inovio Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Inovio Pharmaceuticals position peaked at $39K in Q3 2025.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.